Larry buys OSIR 15.76: Osiris Reports First Quarter 2014 Results: Revenue Up 25% and Gross Margin Improved from 73% to 78%
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the first quarter of 2014. Highlights and . ... ...
40 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home